nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucociliary Clearance
Conditions
Mucociliary Clearance
Trial Timeline
May 1, 2004 → Sep 1, 2005
NCT ID
NCT00325767About nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)
nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose) is a approved stage product being developed by Sumitomo Pharma for Mucociliary Clearance. The current trial status is completed. This product is registered under clinical trial identifier NCT00325767. Target conditions include Mucociliary Clearance.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00325767 | Approved | Completed |
Competing Products
1 competing product in Mucociliary Clearance
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HFO-1234ze(E) + HFA-134a | AstraZeneca | Phase 3 | 77 |